Real‐world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib

Abstract

In our study, we find comparable, though slightly inferior, overall, and progression-free survival, and discontinuation due to toxicity was higher compared with clinical trials. Patient training and information may improve treatment adherence outside clinical trials.